7 Best Peptides for Smoking Cessation

What to Know Before Choosing a Peptide for Smoking Cessation

No peptide is currently FDA-approved specifically for smoking cessation. That is the honest starting point. The compounds in this guide earn their place not because regulators have signed off on them for this use, but because people are actively using them or discussing using them for this goal. FDA-approved medications used off-label, telemedicine-accessible prescriptions, and research-only chemicals are all eligible under the same criterion: real use and real discussion in the context of quitting nicotine. Evidence strength is stated honestly inside each entry rather than used as a filter for who gets included.

The field here is genuinely mixed. GLP-1 receptor agonists, the peptide class that includes semaglutide and exenatide, have actual randomized controlled trial data behind them for cessation-adjacent outcomes. Other compounds, including Selank, Semax, and NAD+, appear primarily in community protocols where users report managing withdrawal symptoms, with little or no controlled human trial data to support those reports. Both kinds of compound belong on this list, and both get their evidence described plainly.

One note on NAD+: it is technically a coenzyme and not a peptide. It appears here because it shows up consistently alongside peptide-based cessation protocols in the biohacking and research community, and leaving it out would leave a gap the reader would notice.

The entries are numbered by how prominently each compound appears in research and documented real-world use for this goal. That is an ordering, not a ranking. The number in front of an entry is not a verdict that this compound is better than the one below it for you. The right choice depends on your health history, your goals, and factors the app is built to help you sort through.

1. Exenatide: The Strongest Human Trial Data for Cessation

Exenatide is a synthetic peptide modeled on a naturally occurring compound. It belongs to the GLP-1 receptor agonist class, meaning it mimics glucagon-like peptide-1, a hormone the gut releases after eating that signals fullness and modulates blood sugar. It has been FDA-approved for type 2 diabetes for years, but its relevance here is entirely different: it has the most robust human clinical trial data of any peptide currently discussed for smoking cessation.

In a pilot randomized controlled trial, 84 overweight or prediabetic smokers were assigned to either exenatide plus a nicotine patch or a placebo plus a nicotine patch. The exenatide group reached a 46 percent abstinence rate compared to roughly 27 percent in the placebo group, a difference that was statistically meaningful. The group also gained about five and a half fewer pounds than the control group, which matters because post-cessation weight gain is one of the most common reasons people relapse.

The mechanism runs through the brain's reward circuitry. GLP-1 receptors are present in the nucleus accumbens and ventral tegmental area, two regions central to how nicotine produces pleasure. When exenatide activates those receptors, it dampens the dopamine release that nicotine normally triggers. A second pathway operates simultaneously: GLP-1 receptor activation in a region called the medial habenula amplifies the aversive, unpleasant feelings associated with nicotine intake, adding a brake to the reward signal from a different direction.

The population caveat matters and should not be glossed over. The positive abstinence results came specifically from overweight or prediabetic smokers. Whether the mechanism holds equally in metabolically healthy, normal-weight smokers has not been established in controlled research. Exenatide is a prescription medication and is not approved for cessation use; any off-label use requires a prescribing physician.

2. Semaglutide: The Most Widely Discussed GLP-1 for Quitting Nicotine

Semaglutide is currently the most visible GLP-1 receptor agonist in both clinical and community settings, approved for chronic weight management and type 2 diabetes. Its profile in the smoking cessation conversation is driven by the convergence of strong mechanistic plausibility, preclinical data showing reduced nicotine self-administration in animal models, and a consistent volume of community reports.

Users in peptide and biohacking forums describe semaglutide as among the more effective compounds they have tried for ending long-term nicotine addiction. Several report that the desire to smoke simply faded rather than requiring active resistance. A pattern that recurs across independent accounts is a broad reduction in addictive behavior across multiple areas simultaneously, with nicotine, alcohol, and high-sugar foods all becoming less compelling at once. This is consistent with the mechanism: GLP-1 receptors modulate reward valuation across multiple behavioral domains, not only eating.

The clinical evidence for cessation specifically is still developing. A randomized trial demonstrating prevention of post-cessation weight gain with semaglutide has been cited in the literature, and at least one planned randomized controlled trial targeting abstinence as a primary outcome was registered as of 2026. The abstinence evidence is anticipated rather than established. The weight management data, on the other hand, is strong and directly relevant, because weight gain is a significant trigger for relapse, and semaglutide's effect on post-cessation weight is one of the more defensible reasons it appears in cessation conversations.

Semaglutide is a prescription medication available via physician or telehealth for weight management or diabetes. Off-label prescribing specifically for smoking cessation sits in a regulatory gray area that varies by jurisdiction and provider.

3. Retatrutide: The Community Frontrunner Among Research-Stage Compounds

Retatrutide is a triple receptor agonist that activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. It is in Phase 3 clinical trials for obesity as of mid-2026 but is not FDA-approved for any indication. It exists at this moment exclusively as a research chemical, and that matters for how to interpret what follows.

Within the peptide community, retatrutide has become the most discussed compound specifically for smoking cessation. The reported mechanism is visceral rather than abstract: users describe nicotine becoming physically repulsive while using retatrutide. The nausea and dizziness that can accompany both nicotine intake and the compound itself apparently combine in a way that makes the act of smoking aversive rather than rewarding. Community threads include accounts of people quitting after decades of smoking. These are user-reported experiences, not controlled data, and cannot be generalized or treated as a reliable prediction for any individual.

The underlying pharmacology is plausible. Adding glucagon receptor agonism to the GLP-1 pathway may amplify the aversion circuitry more than a GLP-1 agonist alone. Some community discussion suggests the triple agonism produces a stronger and faster shift in reward valuation than semaglutide or tirzepatide. Whether that plays out in controlled research remains to be seen, because no randomized controlled trial specifically targeting smoking cessation with retatrutide has been published or registered as of mid-2026. The evidence here is entirely community-reported, with the limitations that entails: self-selected users, no control groups, and reporting bias toward positive outcomes.

4. Tirzepatide: A Dual Agonist with an Active Cessation Trial

Tirzepatide is a dual GIP and GLP-1 receptor agonist, FDA-approved for type 2 diabetes and obesity. It occupies a position between semaglutide and retatrutide in the cessation conversation: more clinical infrastructure around it than retatrutide, less completed cessation-specific evidence than exenatide.

The notable development on tirzepatide for cessation is that a multi-site randomized clinical trial specifically targeting smoking cessation is underway as of 2026. That is a step the other compounds in this class have not yet taken in equivalent form. The trial is evaluating both abstinence outcomes and post-cessation weight management, which reflects the dual rationale for GLP-1 class agents: direct craving reduction alongside prevention of the weight gain that drives relapse.

Community reports position tirzepatide as helpful for reducing cravings but describe it as less likely to produce full cessation than retatrutide. The distinction may come down to pharmacology. The glucagon receptor component in retatrutide appears to contribute meaningfully to the aversion effect users describe most vividly; tirzepatide lacks that third receptor target. These comparisons are drawn from user-reported experience and are not derived from head-to-head clinical data.

Tirzepatide requires a prescription and is not approved for cessation. Like semaglutide, its availability for off-label cessation use depends on the prescriber and jurisdiction.

5. Selank: For Managing Withdrawal Anxiety and Neurochemical Instability

Selank is a synthetic heptapeptide, a seven-amino-acid compound, developed in Russia as a synthetic analog of tuftsin, which is an endogenous tetrapeptide involved in immune regulation. It was researched primarily in Soviet and post-Soviet institutions for anxiety and stress, and it is the most prominent non-GLP-1 peptide used in community cessation protocols.

Its appeal in the cessation context is mechanistic. Nicotine withdrawal is not only about cravings. It produces anxiety, irritability, anhedonia (a flattening of the capacity to feel pleasure), and neurochemical instability that makes the early weeks of quitting genuinely difficult. Selank works through GABAergic modulation, meaning it interacts with the same inhibitory neurotransmitter system that benzodiazepines target, but without the dependence profile associated with that drug class. It also upregulates BDNF, brain-derived neurotrophic factor, a protein involved in neuronal repair and synaptic plasticity, which is relevant during a period when the brain is actively rewiring away from nicotine dependence.

Community accounts describe Selank as stabilizing rather than eliminating cravings. Users in nootropics and peptide research forums cite it for making withdrawal physiologically manageable, reducing the anxiety peak that frequently drives relapse in the first two weeks. It is often combined with Semax and NAD+ in community protocols, with each compound targeting a different dimension of withdrawal.

No peer-reviewed human randomized controlled trial exists for Selank in smoking cessation as of 2026. Some human data on its anxiety effects comes from Russian clinical literature, but that research has not been replicated in Western settings and does not address cessation directly. Selank is a research chemical in the United States and most Western jurisdictions, not approved for human use by the FDA.

6. Semax: For Cognitive Fog and Dopamine Stability During Withdrawal

Semax is a synthetic peptide analog of a fragment of adrenocorticotropic hormone, specifically the ACTH(4-7) sequence. It was developed in Russia for neuroprotection and cognitive enhancement and is used intranasally in some Eastern European clinical contexts. In the United States and most of Western Europe, it is available only as a research chemical.

Its presence in smoking cessation protocols is more focused than Selank's. Where Selank addresses the anxiety and emotional volatility of withdrawal, Semax is used specifically for the cognitive dimension: difficulty concentrating, mental fog, and the dopamine receptor instability that follows removal of a compound that was artificially elevating dopamine tone for years. Semax stimulates BDNF production and appears to stabilize dopamine signaling, which is why it appears repeatedly alongside Selank in community cessation stacks rather than as a standalone compound.

The evidence here is experiential rather than clinical. No peer-reviewed randomized controlled trial has been published for Semax in smoking cessation as of 2026. What exists is a pattern of community use concentrated in nootropics and peptide research forums, where users describe Semax as useful for the cognitive recovery phase of cessation rather than for acute craving management. One community account that circulated in nootropics discussions described a person who reported being nicotine-free for three years using a stack that included Semax alongside Selank and NAD+.

Semax is not approved for human use in the United States. It should not be conflated with the FDA-approved prescription medications covered earlier in this list.

7. NAD+: Cellular Support for the Energy and Neurochemical Crash of Quitting

NAD+, or nicotinamide adenine dinucleotide, is a coenzyme present in every living cell. It is not a peptide. It appears here because it shows up consistently in community cessation protocols alongside peptide compounds, and omitting it would leave a gap in what people actually use for this goal.

Its relevance to smoking cessation rests on several interrelated mechanisms. Chronic tobacco use depletes cellular NAD+ levels over time by driving increased consumption through oxidative stress and DNA damage pathways. When someone quits, this depletion contributes to the fatigue, cognitive difficulty, and physical depletion that characterize early withdrawal. Replenishing NAD+ is proposed to address this energy and neuroprotective deficit by restoring mitochondrial function and activating sirtuins, a class of proteins involved in cellular repair and stress resistance. The term mitochondrial function refers to the process by which cells generate usable energy from nutrients; when that process runs below capacity, the result is the kind of pervasive fatigue that makes quitting harder. NAD+ is also involved in the neurotransmitter synthesis pathways that converge on dopaminergic tone, which is why community users describe it as supportive of the broader neurochemical recovery process.

In practice, NAD+ is used in multiple forms in community cessation protocols: intranasal sprays, sublingual drops, and subcutaneous injection are all reported in biohacking communities. Some specialized addiction clinics use high-dose intravenous NAD+ protocols across multiple sessions as an adjunct to formal cessation programs. This clinical practice is not supported by major cessation guidelines, and the evidence base is observational rather than controlled.

The community characterization of NAD+ is consistently supportive rather than primary: it manages the neurochemical damage and energy depletion of cessation but does not directly reduce nicotine cravings the way GLP-1 receptor agonists do. Users who report long-term success often describe using NAD+ as part of a stack, typically with Semax and Selank, rather than as a standalone intervention. No peer-reviewed randomized controlled trial has been published for NAD+ specifically in smoking cessation as of 2026. Oral NAD+ precursors such as NMN and NR are sold as dietary supplements in the United States. Intravenous NAD+ administration exists in compounding pharmacy and clinical addiction settings, where its regulatory status varies by state and provider.

How These Peptides Compare

Frequently Asked Questions

Are GLP-1 Peptides Legal to Use for Smoking Cessation?

GLP-1 receptor agonists like exenatide, semaglutide, tirzepatide, and liraglutide are FDA-approved prescription medications, but none are approved specifically for smoking cessation. Off-label prescribing by a physician is legal in the United States and is how most people access them for this purpose, though availability through telemedicine platforms specifically for cessation varies by provider and state. Research-only compounds like Selank, Semax, and retatrutide are not approved for human use by the FDA and exist in a different legal category entirely.

Do Any of These Actually Help People Quit, or Is the Evidence Mostly Hype?

The honest answer varies considerably by compound. Exenatide produced a statistically significant improvement in abstinence rates in a randomized controlled trial, though the results were specific to overweight or prediabetic smokers and were achieved alongside a nicotine patch. Semaglutide and tirzepatide have strong mechanistic rationale and consistent community reports, but their cessation-specific randomized trial data is either planned or underway rather than published. Selank, Semax, and NAD+ rest primarily on community-reported experience with no controlled human trial data for this use as of 2026, which means confidence in those compounds is lower and individual variability is higher.

Why Do GLP-1 Medications Affect the Desire to Smoke?

GLP-1 receptors are expressed in two brain regions central to nicotine dependence. In the nucleus accumbens and ventral tegmental area, GLP-1 receptor activation reduces the dopamine release that nicotine normally triggers, dialing down the reward signal. Simultaneously, activation in the medial habenula amplifies the aversive feelings associated with nicotine intake. Together, nicotine becomes less rewarding and more unpleasant, which is the same directional effect that the most effective non-peptide cessation medications produce, via a different molecular pathway.

Can These Peptides Replace Nicotine Replacement Therapy or Varenicline?

No peptide in this guide has been studied as a direct replacement for FDA-approved cessation pharmacotherapy. In the exenatide trial that produced the strongest positive results, the compound was used alongside a nicotine patch rather than instead of it. GLP-1 receptor agonists appear to work best as an adjunct to existing cessation support, not as a substitute for it. Research-only compounds like Selank and Semax are used in community protocols to manage specific withdrawal symptoms, which is a different role from the craving-suppression mechanism of varenicline.

How Long Before Any of These Produce a Noticeable Effect?

For GLP-1 compounds studied in clinical research, cessation effects were evaluated over treatment periods lasting several weeks to a couple of months, with abstinence outcomes assessed at the end of that window. Community users describing semaglutide and retatrutide sometimes report noticing a shift in their desire to smoke within the first few weeks of use, though this is user-reported experience rather than a controlled finding. For support compounds like Selank and NAD+, community accounts suggest withdrawal manageability begins within days but varies considerably across individuals.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for smoking cessation in one place.